N/A
Completed N=122
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
Source: ClinicalTrials.gov NCT04450108 ↗Enrolled (actual)
122
Serious AEs
0.0%
Results posted
Jun 2022
Primary outcomePrimary: Change in FeNO Value — -26.1 percent change — p=<0.001
Summary
This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in FeNO Value |
-26.1 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Subject is 7 to 80 years of age.
- Has asthma
- Has been identified as a candidate for inhaled corticosteroid (ICS) treatment
- Is willing and able to perform Vivatmo pro™ testing
Exclusion Criteria
- Subject has used corticosteroids prior to enrollment.
- Subject has other current serious medical conditions
- Subject has not been clinically stable for at least 2 weeks prior to the study
- Subject is unwilling or unable to perform Vivatmo pro testing
Data sourced from ClinicalTrials.gov (NCT04450108). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.